Drug distribution giant McKesson Corporation (NYSE:MCK) reported third-quarter earnings after the market closed on Jan. 30, 2012. The stock rallied, as earnings came in ahead of expectations and management announced additional share repurchases. The company has had a strong run of leveraging modest sales growth into double-digit annual profit gains, and there appears to be very few obstacles in its way to continuing this impressive run. A reasonable valuation and continued wave of generic drug introductions also bode well for investors.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Third Quarter Recap
Revenues advanced 9% to $30.8 billion. The flagship distribution solutions unit, which distributes drugs, medical supplies and equipment, as well as health and beauty care products, also reported a 9% top line advance to account for the vast majority of total revenue at 97.3%. Drugstore chains CVS (NYSE:CVS) and Rite Aid (NYSE:RAD) account for a high percentage of sales at roughly a quarter of total revenues.

The remainder of sales stem from Technology Solutions, which helps hospitals such as HMA (NYSE:HMA) and Universal Health Services (NYSE:UHS) as well as related healthcare providers use technology to better manage their supply chain and financial operations. This segment saw sales rise a modest 4%.

Despite its small relative size, Technology Solutions is quite profitable and accounted for 12% of McKesson's $579 million in divisional operating profits. Backing out corporate overhead, total company operating income reached $492 million, up 60% from last year's third quarter. Both quarters contained litigation charges, but they were much larger last year at $189 million last year to dent reported profitability.

Reported net income nearly doubled to $300 million, while share buybacks helped earnings per diluted share double to $1.22. On an adjusted basis, the company estimated that recurring earnings advanced a more modest 9% to $1.40 per diluted share. (To know more about income statements, read Understanding The Income Statement.)

For the full year, analysts project revenue growth of 8.3% and total sales just north of $121.34 billion. McKesson expects to report earnings between $6.22 and $6.47 per diluted share.

The Bottom Line
Acquisitions and organic growth continue to allow McKesson to report solid revenue growth. A recent acquisition was also announced for Katz Group Canada, an integrated retail pharmacy network in Canada. Annual sales growth over the past five years has been more modest at around 5%, but management has been able to leverage that into much higher annual profit growth closer to 14%.

At a forward P/E of roughly 11, the valuation continues to be reasonable given the level of profit growth McKesson has posted in recent years. Drug distribution firms also garner higher profits on generic drugs, and with a continued wave of drugs losing patent protection, McKesson should continue to face tailwinds when it comes to profit growth. (For additional reading, check out 5 Must-Have Metrics For Value Investors.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!